Multiparametric magnetic resonance imaging (MRI) of the prostate is now recommended as the initial diagnostic test for men presenting with suspected prostate cancer, with a negative MRI enabling safe avoidance of biopsy and a positive result enabling MRI-directed sampling of lesions. The diagnostic pathway consists of several steps, from initial patient presentation and preparation to performing and interpreting MR images, communicating the imaging findings, outlining the prostate and intra-prostatic target lesions, performing the biopsy, and assessing the cores. Each component of this pathway requires experienced clinicians, optimised equipment, good inter-disciplinary communication between specialists, and standardised workflows in order to achieve the expected outcomes. Assessment of quality and mitigation measures are essential for the success of the MRI-directed prostate cancer diagnostic pathway. Quality assurance processes including Prostate Imaging-Reporting and Data System (PI-RADS), template biopsy, and pathology guidelines help minimise variation and ensure optimisation of the diagnostic pathway. Quality control systems including the Prostate Imaging Quality (PI-QUAL) scoring system, patient-level outcomes (such as PI-RADS MRI score assignment and cancer detection rates), multidisciplinary meeting review and audits might also be used to provide consistency of outcomes and ensure that all the benefits of the MRI-directed pathway are achieved.
Key points-Multiparametric magnetic resonance imaging (MRI) is now recommended as the initial diagnostic test for men presenting with suspected prostate cancer -A negative MRI enables patients to safely avoid biopsy, whereas a positive MRI prompts targeted biopsy and pathologically accurate tissue sampling.-The MRI-directed prostate cancer diagnostic pathway involves several steps including acquiring and interpreting MR images, communicating MRI findings, outlining suspicious target lesions, performing biopsy, and evaluating the cores.-All steps in the pathway are prone to variation; assessment and mitigation of poor quality and variance are essential for a successful delivery of the MRI-directed pathway -Quality assurance systems to minimise variation in performance and prevent poor quality include Prostate Imaging-Reporting and Data System (PI-RADS) imaging guidelines for radiologists, prostate biopsy templates, and International Society of Urological Pathology (ISUP) guidelines for histopathologists.-Quality control measures include checking MRI compliance with PI-RADS, image quality assessment with the Prostate Imaging Quality (PI-QUAL) scoring system, radiologist certification, multidisciplinary team meeting ( MDT) review and pathology re-review of images, and audits of cancer detection rates and biopsy core quality.